Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 7
2010 3
2011 3
2012 1
2013 1
2014 3
2015 3
2016 8
2017 5
2018 13
2019 10
2020 20
2021 16
2022 27
2023 18
2024 30
2025 32
2026 33

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean daigo kayo (1 results)?
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suárez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Motzer RJ, et al. Lancet. 2026 Aug 29;408(10557):808-820. doi: 10.1016/S0140-6736(26)01089-5. Epub 2026 Aug 12. Lancet. 2026. PMID: 42586114 Clinical Trial.
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Kidani Y, Nogami W, Yasumizu Y, Kawashima A, Tanaka A, Sonoda Y, Tona Y, Nashiki K, Matsumoto R, Hagiwara M, Osaki M, Dohi K, Kanazawa T, Ueyama A, Yoshikawa M, Yoshida T, Matsumoto M, Hojo K, Shinonome S, Yoshida H, Hirata M, Haruna M, Nakamura Y, Motooka D, Okuzaki D, Sugiyama Y, Kinoshita M, Okuno T, Kato T, Hatano K, Uemura M, Imamura R, Yokoi K, Tanemura A, Shintani Y, Kimura T, Nonomura N, Wada H, Mori M, Doki Y, Ohkura N, Sakaguchi S. Kidani Y, et al. Among authors: kato t. Proc Natl Acad Sci U S A. 2022 Feb 15;119(7):e2114282119. doi: 10.1073/pnas.2114282119. Proc Natl Acad Sci U S A. 2022. PMID: 35140181 Free PMC article.
GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment.
Yamamichi G, Kato T, Arakawa N, Ino Y, Ujike T, Nakano K, Koh Y, Motoyama Y, Outani H, Myoba S, Ishizuya Y, Yamamoto Y, Hatano K, Kawashima A, Fukuhara S, Uemura H, Okada S, Morii E, Nonomura N, Uemura M. Yamamichi G, et al. Among authors: kato t. Biomark Res. 2024 Nov 25;12(1):147. doi: 10.1186/s40364-024-00695-6. Biomark Res. 2024. PMID: 39587633 Free PMC article.
The era of immunogenomics/immunopharmacogenomics.
Zewde M, Kiyotani K, Park JH, Fang H, Yap KL, Yew PY, Alachkar H, Kato T, Mai TH, Ikeda Y, Matsuda T, Liu X, Ren L, Deng B, Harada M, Nakamura Y. Zewde M, et al. Among authors: kato t. J Hum Genet. 2018 Jul;63(8):865-875. doi: 10.1038/s10038-018-0468-1. Epub 2018 May 21. J Hum Genet. 2018. PMID: 29785006 Review.
Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer.
Tani M, Hatano K, Ishizuya Y, Oka T, Kanaki T, Inoguchi S, Yoshimura A, Horibe Y, Liu Y, Nesrine S, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Yamaguchi T, Obika S, Yusa K, Nonomura N, Nimura K. Tani M, et al. Among authors: kato t. Cancer Sci. 2025 Dec;116(12):3403-3416. doi: 10.1111/cas.70194. Epub 2025 Sep 16. Cancer Sci. 2025. PMID: 40957713 Free PMC article.
Genomic alteration and clinical significance of circulating tumor DNA in patients with advanced urothelial cancer: SCRUM-Japan monstar screen project.
Osawa T, Matsubara N, Kato T, Shiota M, Nishimoto K, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Abutani H, Oda T, Fujisawa T, Nakamura Y, Sivakumar S, Eto M, Yoshino T, Nonomura N. Osawa T, et al. Among authors: kato t. NPJ Precis Oncol. 2025 Nov 18;9(1):362. doi: 10.1038/s41698-025-01154-7. NPJ Precis Oncol. 2025. PMID: 41254099 Free PMC article.
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
Kato T, Nakai Y, Sato M, Takao T, Iwanishi T, Toyoda S, Osaki H, Tsujihata M, Okada K, Kakimoto K, Horitani H, Ono Y, Nishimura K, Takada S, Fujita K, Takayama H, Miyake O, Nakayama M, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nonomura N. Kato T, et al. Sci Rep. 2025 Dec 12;15(1):43676. doi: 10.1038/s41598-025-27578-6. Sci Rep. 2025. PMID: 41387488 Free PMC article.
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire.
Rosenberger L, Hansmann L, Anastasopoulou V, Wolf SP, Drousch K, Moewes C, Feng X, Cao G, Huang J, Yew PY, Strønen E, Kato T, Saligrama N, Olweus J, Nakamura Y, Willimsky G, Blankenstein T, Schreiber H, Leisegang M. Rosenberger L, et al. Among authors: kato t. J Immunother Cancer. 2025 May 2;13(5):e011351. doi: 10.1136/jitc-2024-011351. J Immunother Cancer. 2025. PMID: 40316304 Free PMC article.
206 results